Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study
Late-breaking data presented from a Phase 2a trial at UEG Week 2019, Barcelona, Spain, highlights potential of investigational medicine to prevent gluten induced immune activation in patients with celiac disease...
Read More
Presentation: Phase 2 Celiac Disease Data from UEG Week 2019
View Presentation Here
Read More
Cour Pharmaceuticals Receives FDA Fast Track Designation for TIMP-GLIA
Cour Pharmaceuticals Receives FDA Fast Track Designation for TIMP-GLIA – A Novel Treatment for Celiac Disease under Clinical Development TIMP-GLIA is designed to enable patients to develop tolerance to gluten...
Read More
Cour Pharmaceuticals Announces an Open Investigational New Drug (IND) Application for TIMP-GLIA – A Novel Treatment for Celiac Disease
Cour Pharmaceuticals, a specialty pharma company focused on autoimmune, allergic, and inflammatory diseases, announces that its Investigational New Drug (IND) for TIMP-GLIA is now open with the US Food &...
Read More
Takeda and Cour Partner to Develop Novel Therapies for Celiac Disease
Takeda and Cour Partner to Develop Novel Therapies for Celiac Disease and Other Gastrointestinal Diseases Osaka, Japan, December 8, 2015, and Chicago, Ill., December 7, 2015 – Takeda Pharmaceutical Company...
Read More
Cour Pharmaceuticals Releases Data on Potential Breakthrough Treatment for Celiac Disease
Proprietary Antigen-specific Nanoparticles and Cure for Celiac Disease Chicago (June 22, 2015) – Cour Pharmaceutical Development Company today announced new data from a preclinical live animal study demonstrating a breakthrough...
Read More